Browse

Galactosylated Poly(Ethyleneglycol)-Lithocholic Acid Selectively Kills Hepatoma Cells, While Sparing Normal Liver Cells

Cited 9 time in Web of Science Cited 8 time in Scopus
Authors
Gankhuyag, Nomundelger; Singh, Bijay; Maharjan, Sushila; Choi, Yun-Jaie; Cho, Chong-Su; Cho, Myung-Haing
Issue Date
2015-06
Citation
Macromolecular Bioscience, Vol.15 No.6, pp.777-787
Keywords
anti-cancer drugsapoptosishepatocyte-specificlithocholic acidnanoparticles
Abstract
Delivering drugs selectively to cancer cells but not to nearby normal cells is a major obstacle in drug therapy. In this study, lithocholic acid (LCA), a potent anti-cancer drug, is converted to two forms of poly(ethyleneglycol) (PEG) conjugates, viz., PEG-LCA (PL) and lactobionic acid (LBA) conjugated PEG-LCA (LPL). The latter form contains a galactose ligand in LBA to target the hepatocytes. Both forms are self-assembled to form nanoparticle formulation, and they have high potency than LCA to kill HepG2 cancer cells, sparing normal LO2 cells. Besides, LPL has high specificity to mouse liver cells in vivo. Western blot results confirm that the cell death is occurred through apoptosis induced by LPL nanoparticles. In conclusion, the induction of apoptosis and cell death is much more efficient with LPL nanoparticles than LCA molecules.
ISSN
1616-5187
URI
https://hdl.handle.net/10371/172467
DOI
https://doi.org/10.1002/mabi.201400475
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Veterinary Medicine (수의과대학)Dept. of Veterinary Medicine (수의학과)Journal Papers (저널논문_수의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse